Full-Time
Delivers precision radiation therapy equipment
No salary listed
Hamburg, Germany
Remote
Elekta specializes in precision radiation medicine, delivering devices and software that help clinicians treat cancer and brain disorders. Its core products are radiation therapy equipment (such as linear accelerators and advanced radiosurgery platforms) and treatment-planning and clinical workflow software. These tools work together: the hardware delivers targeted ionizing radiation to tumors while imaging and planning software optimize dose exactly where it is needed, then guide clinicians through the treatment workflow. Elekta differentiates itself by offering an integrated hardware-software ecosystem with a global installed base, a focus on reaching underserved markets, and ongoing services to support clinicians and facilities. The company's goal is to improve patient outcomes by expanding access to high-quality radiation therapy and growing its installed base around the world.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Stockholms kommun, Sweden
Founded
1972
People at Elekta who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Paid Vacation
Hybrid Work Options
Wellness Program
Tuition Reimbursement
Elekta presents advancements in mr-guided radiotherapy at ESTRO 2026. By News Release Published Date: May 20, 2026 Recent research showcased at the European Society for Radiotherapy and Oncology (ESTRO) 2026 conference in Stockholm has emphasized significant strides in MR-guided adaptive radiotherapy across various cancer types. Elekta, the medical technology company, announced findings from over 120 studies by more than 30 international institutions, focusing on cancer treatments for breast, lung, pancreas, liver, kidney, and bladder, among others. The new data underscores the benefits of high-quality imaging paired with adaptive techniques in refining radiotherapy delivery. This approach may facilitate more precise and less invasive treatments that maintain clinical efficacy. John Christodouleas, MD, MPH, Elekta's Head of Medical Affairs and Partner Research, highlighted the value of seeing the targets during treatment, stating, "The emerging evidence at ESTRO demonstrates how this principle manifests in the everyday reality of clinical care." Prostate Cancer: Towards Shorter Treatments In a plenary session, the HERMES study from The Royal Marsden examined the use of two-fraction MR-guided radiotherapy for prostate cancer facilitated by the Elekta Unity MR-Linac. This technology allows clinicians to visualize the prostate and adjacent organs in real-time, adapting the treatment delivery - a crucial step when higher dose levels per session are involved. The study indicated favorable tolerability and the potential to drastically reduce the length of treatment protocols, which could lower the healthcare burden for patients. Rectal Cancer: Supporting Organ Preservation Research presented from the University of Tübingen's MARS protocol demonstrated that MR-guided adaptive radiotherapy using the Elekta Unity MR-Linac aids in organ preservation strategies in rectal cancer patients. Effective dose escalation and adaptive treatment approaches have shown high response rates, enabling the possibility of non-operative management without the need for immediate surgery and preserving bowel function. Liver Metastases: Enhanced Precision Treatments A comprehensive international analysis from the MOMENTUM and OligoCare registries focused on patients with liver oligometastases. It was noted that while stereotactic radiotherapy maintains strong tumor control, MR-guidance provides enhanced precision, potentially reducing the need for higher doses required by standard CBCT-guidance. This capability allows effective treatment delivery in challenging anatomical conditions, thereby improving the therapeutic ratio.
Elekta AB reported 2% revenue growth in Q3 2026, with gross margin improving 120 basis points to 38.3% and EBIT margin rising to 11.9%. The company achieved a book-to-bill ratio of 1.17, supported by strong momentum in Europe and growth in China. However, the quarter was significantly impacted by foreign exchange headwinds, with currency reducing net sales by over SEK500 million. The Americas region experienced a 6% sales decline. Elekta incurred restructuring charges exceeding SEK400 million but expects total costs under SEK500 million, with run-rate savings of over SEK500 million from Q1 next year. Net debt decreased by more than SEK200 million year-on-year. The company successfully launched Elekta Evo in the US and maintains leadership in China's underpenetrated radiotherapy market.
Elekta appoints Nexeva Healthcare Solutions as strategic partner in South Africa. Enhanced local service model to strengthen radiotherapy support, clinical capability and lifecycle management 3 Mar 2026 The agreement between Elekta and Nexeva Healthcare Solutions was formalised during the World Health Expo held in Dubai in February 2026. Back row (left to right): Ozgur Temel, head of sub-Saharan Africa at Elekta; Laurent Leksell, chairman of the board, Elekta; Marga Claassen, medical physicist and regional sales manager at Nexeva; Tomas Eliasson, vice chair of the board; Anthony Pedersen, CEO, Icon Healthcare Holdings. Front (seated): Simon Meredith, managing director Nexeva Healthcare Solutions; Feras Al Hassan, VP service and sales operations, Elekta. Elekta has appointed Nexeva Healthcare Solutions as its strategic partner in South Africa under a multi-year agreement. The appointment introduces a strengthened local operating model designed to enhance technical support, clinical engagement and commercial responsiveness for radiotherapy centres across both the private and public healthcare sectors. The agreement was formally signed during the World Health Expo in Dubai in February 2026, underscoring the strategic importance of the South African market within Elekta's broader regional framework. The signing brought together senior leadership from both organisations, reinforcing the long-term nature of the collaboration and its focus on strengthening radiotherapy delivery capacity across South Africa. Strengthening radiotherapy infrastructure. South Africa's oncology sector continues to operate under significant capacity pressure, where uptime, service responsiveness and access to clinical training are critical. The Elekta - Nexeva collaboration combines Elekta's global radiotherapy innovation and standards with Nexeva's established local healthcare footprint and service capability. Under the agreement, customers can expect: * Expanded field service engineering capacity in South Africa * Enhanced commercial and technical support * Closer clinical engagement, including applications and training support * Continued focus on installations, commissioning, upgrades and lifecycle management The partnership is structured to improve response times, strengthen local accountability and support long-term sustainability of radiotherapy services in the region. Elekta will maintain a lean, focused local team in South Africa, working in alignment with Nexeva to support customers and partners. Continuity of standards and patient safety. Elekta confirmed that equipment standards, quality systems and patient safety commitments remain unchanged. Nexeva will operate in full alignment with Elekta's global processes and performance standards, ensuring continuity across service, clinical support and commercial engagement. Simon Meredith, managing director at Nexeva Healthcare Solutions, said the appointment reflects a strategic commitment to strengthening oncology infrastructure in South Africa. "Radiotherapy centres operate in high-demand environments where reliability and rapid response are essential. This partnership enables us to combine Elekta's globally recognised technology with an agile, locally embedded support model that is responsive to the realities of South African healthcare." "Our priority is to work closely with clinical and technical teams to minimise downtime, strengthen capability through training and applications support, and ensure long-term lifecycle optimisation of installed systems." Meredith added that the collaboration is designed to support both immediate operational needs and future market development aligned to South Africa's radiotherapy priorities. Transition and implementation. Elekta and Nexeva have already engaged with customers to confirm commercial and technical points of contact, service pathways, escalation processes and alignment on planned installations, upgrades and training schedules. The multi-year agreement signals a long-term commitment to strengthening radiotherapy delivery capacity in South Africa, with a clear focus on service resilience, clinical partnership and sustainable growth. About elekta. As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com. About Nexeva Healthcare Solutions. Nexeva Healthcare Solutions is a South African healthcare solutions provider delivering innovative medical technologies and integrated support services. By combining trusted global innovations with agile local service, Nexeva supports healthcare providers in achieving optimal patient outcomes. Nexeva Health Solutions is a South African MedTech company committed to strengthening healthcare performance through high-quality technologies, responsive service, and clinical support. We partner with leading global manufacturers to bring proven innovations into the local market, ensuring clinicians have access to reliable, cost-effective solutions that enhance precision, efficiency, and continuity of care. Backed by Icon Healthcare's two-decade legacy in value-based care, Nexeva combines deep local expertise with a strong understanding of clinical workflows. Our team supports healthcare providers with integration, training, and ongoing technical service, expanding access to technologies that improve outcomes and enable sustainable, patient-centred healthcare across South Africa.
Elekta has received FDA 510(k) clearance for its Elekta Evo CT-Linac system, enabling its use across United States radiation oncology centres. The system combines high-quality CT imaging with linear accelerator functionality, allowing clinicians to visualise tumours and organs-at-risk more clearly during treatment. Evo features Iris, an AI-enhanced imaging capability that uses algorithms to minimise scatter and improve image reconstruction compared to traditional cone-beam CT imaging. The technology can be added as an upgrade to existing Elekta linear accelerators, extending their useful life whilst lowering adoption barriers. The system is already being used in Europe and other regions. Shares of Elekta rose 3.7% following the announcement, with the stock gaining 38.4% over the past six months.
Elekta has announced a series of leadership changes, including the appointment of Klara Eiritz as chief financial officer.